Cargando…

BM-MSCs differentiated to chondrocytes for treatment of full-thickness cartilage defect of the knee

BACKGROUND: Full-thickness articular cartilage injury of the knee is a major cause of disability. The aim of this study is to assess the outcome of patients treated with differentiated to chondrocytes bone marrow mesenchymal stem cells (BM-MSCs) cultured on a collagen type I/III (Chondro-Gide®) scaf...

Descripción completa

Detalles Bibliográficos
Autores principales: Mardones, Rodrigo, Giai Via, Alessio, Pipino, Gennaro, Jofre, Claudio M., Muñoz, Sara, Narvaez, Edgar, Maffulli, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539404/
https://www.ncbi.nlm.nih.gov/pubmed/33023626
http://dx.doi.org/10.1186/s13018-020-01852-x
_version_ 1783591048012890112
author Mardones, Rodrigo
Giai Via, Alessio
Pipino, Gennaro
Jofre, Claudio M.
Muñoz, Sara
Narvaez, Edgar
Maffulli, Nicola
author_facet Mardones, Rodrigo
Giai Via, Alessio
Pipino, Gennaro
Jofre, Claudio M.
Muñoz, Sara
Narvaez, Edgar
Maffulli, Nicola
author_sort Mardones, Rodrigo
collection PubMed
description BACKGROUND: Full-thickness articular cartilage injury of the knee is a major cause of disability. The aim of this study is to assess the outcome of patients treated with differentiated to chondrocytes bone marrow mesenchymal stem cells (BM-MSCs) cultured on a collagen type I/III (Chondro-Gide®) scaffold. The secondary aim was to confirm the absence of adverse events. METHODS: Fifteen patients (19 knees) with symptomatic full-thickness cartilage defects of the knee were enrolled. Bone marrow was harvested from the iliac crest, BM-MSCs were prepared, and expanded cells were grown in a standard medium or in a standard culture medium containing TGF-β. BM-MSCs differentiated to chondrocytes were seeded in a porcine collagen type I/III scaffold (Chondro-Gide®) and cultured in TGF-β containing media. After 4 weeks, the membrane was sutured on the cartilage defect. All patients underwent plain radiographs (antero-posterior, lateral, and axial view of the patella) and MRI of the affected knee. The Oxford knee score, the Lyhsolm scale, and the VAS score were administered to all patients. At final follow-up a MRI for the study of articular cartilage was undertaken. RESULTS: The mean size of the cartilage lesions was 20 × 17 mm (range, 15 × 10 mm–30 × 30 mm). At final follow-up, the median Oxford knee score and Lyhsolm scale scores significantly improved from 29 (range 12–39; SD 7.39) to 45 (range 24–48; SD 5.6) and from 55.5 (range 25–81; SD 17.7) to 94.5 (58–100; SD 10.8), respectively. Pain, according to the VAS score, significantly improved. Sixty percent of patients reported their satisfaction as excellent, 20% as good, 14% as fair, and 1 patient as poor. CONCLUSION: The treatment of full-thickness chondral injuries of the knee with differentiated to chondrocytes BM-MSCs and Chondro-Gide® scaffold showed encouraging outcomes. Further studies involving more patients, and with longer follow-up, are required to evaluate the effectiveness of the treatment and the long-term results.
format Online
Article
Text
id pubmed-7539404
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75394042020-10-08 BM-MSCs differentiated to chondrocytes for treatment of full-thickness cartilage defect of the knee Mardones, Rodrigo Giai Via, Alessio Pipino, Gennaro Jofre, Claudio M. Muñoz, Sara Narvaez, Edgar Maffulli, Nicola J Orthop Surg Res Research Article BACKGROUND: Full-thickness articular cartilage injury of the knee is a major cause of disability. The aim of this study is to assess the outcome of patients treated with differentiated to chondrocytes bone marrow mesenchymal stem cells (BM-MSCs) cultured on a collagen type I/III (Chondro-Gide®) scaffold. The secondary aim was to confirm the absence of adverse events. METHODS: Fifteen patients (19 knees) with symptomatic full-thickness cartilage defects of the knee were enrolled. Bone marrow was harvested from the iliac crest, BM-MSCs were prepared, and expanded cells were grown in a standard medium or in a standard culture medium containing TGF-β. BM-MSCs differentiated to chondrocytes were seeded in a porcine collagen type I/III scaffold (Chondro-Gide®) and cultured in TGF-β containing media. After 4 weeks, the membrane was sutured on the cartilage defect. All patients underwent plain radiographs (antero-posterior, lateral, and axial view of the patella) and MRI of the affected knee. The Oxford knee score, the Lyhsolm scale, and the VAS score were administered to all patients. At final follow-up a MRI for the study of articular cartilage was undertaken. RESULTS: The mean size of the cartilage lesions was 20 × 17 mm (range, 15 × 10 mm–30 × 30 mm). At final follow-up, the median Oxford knee score and Lyhsolm scale scores significantly improved from 29 (range 12–39; SD 7.39) to 45 (range 24–48; SD 5.6) and from 55.5 (range 25–81; SD 17.7) to 94.5 (58–100; SD 10.8), respectively. Pain, according to the VAS score, significantly improved. Sixty percent of patients reported their satisfaction as excellent, 20% as good, 14% as fair, and 1 patient as poor. CONCLUSION: The treatment of full-thickness chondral injuries of the knee with differentiated to chondrocytes BM-MSCs and Chondro-Gide® scaffold showed encouraging outcomes. Further studies involving more patients, and with longer follow-up, are required to evaluate the effectiveness of the treatment and the long-term results. BioMed Central 2020-10-06 /pmc/articles/PMC7539404/ /pubmed/33023626 http://dx.doi.org/10.1186/s13018-020-01852-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Mardones, Rodrigo
Giai Via, Alessio
Pipino, Gennaro
Jofre, Claudio M.
Muñoz, Sara
Narvaez, Edgar
Maffulli, Nicola
BM-MSCs differentiated to chondrocytes for treatment of full-thickness cartilage defect of the knee
title BM-MSCs differentiated to chondrocytes for treatment of full-thickness cartilage defect of the knee
title_full BM-MSCs differentiated to chondrocytes for treatment of full-thickness cartilage defect of the knee
title_fullStr BM-MSCs differentiated to chondrocytes for treatment of full-thickness cartilage defect of the knee
title_full_unstemmed BM-MSCs differentiated to chondrocytes for treatment of full-thickness cartilage defect of the knee
title_short BM-MSCs differentiated to chondrocytes for treatment of full-thickness cartilage defect of the knee
title_sort bm-mscs differentiated to chondrocytes for treatment of full-thickness cartilage defect of the knee
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539404/
https://www.ncbi.nlm.nih.gov/pubmed/33023626
http://dx.doi.org/10.1186/s13018-020-01852-x
work_keys_str_mv AT mardonesrodrigo bmmscsdifferentiatedtochondrocytesfortreatmentoffullthicknesscartilagedefectoftheknee
AT giaiviaalessio bmmscsdifferentiatedtochondrocytesfortreatmentoffullthicknesscartilagedefectoftheknee
AT pipinogennaro bmmscsdifferentiatedtochondrocytesfortreatmentoffullthicknesscartilagedefectoftheknee
AT jofreclaudiom bmmscsdifferentiatedtochondrocytesfortreatmentoffullthicknesscartilagedefectoftheknee
AT munozsara bmmscsdifferentiatedtochondrocytesfortreatmentoffullthicknesscartilagedefectoftheknee
AT narvaezedgar bmmscsdifferentiatedtochondrocytesfortreatmentoffullthicknesscartilagedefectoftheknee
AT maffullinicola bmmscsdifferentiatedtochondrocytesfortreatmentoffullthicknesscartilagedefectoftheknee